DEL-1 can inhibit inflammation through various anti-inflammatory effects to alleviate IL-17-mediated conditions, such as inflammatory bone loss and multiple sclerosis, suggesting that DEL-1 may be a potential target for the treatment of hypertension (45, 48). Here, EDIL3 is linked to hypertensive disorder.